Gary Lee, PhD

Dr. Lee is a veteran biotech executive with over a decade of experience leading cell and gene therapy programs for human applications. As VP of Cell Therapy at Sangamo Therapeutics, Dr. Lee led the company’s programs around T-cell engineering, including CAR-T cell therapies for oncology applications (a platform recently licensed to Kite, a Gilead company) and T-cell therapies for HIV. Dr. Lee also served as the head of Sangamo’s immunology/Treg therapeutic pipeline. Dr. Lee received his B.S. in Chemical Engineering from California Institute of Technology and his Ph.D. in Chemical Engineering from U.C. Berkeley.
Speaking In
8:30 AM - 9:40 AM
Tuesday, October 22
As the industry continues to do revolutionary research on cancer, a host of new treatment options…
10:45 AM - 11:40 AM
Tuesday, October 22
Gene therapies have the potential to increase the healthspan of patients and offer new approaches…
9:15 AM - 9:30 AM
Wednesday, October 23
Senti Biosciences is a Series A next-generation biotechnology company that designs gene circuits…